In an era where convenience and efficiency stand as pillars of service delivery, HealthLynked (OTCQB: HLYK) has introduced an innovative online patient booking system, akin to how OpenTable simplifies restaurant reservations. This seamless integration of technology and healthcare is transforming how patients interact with medical services, ensuring that setting up a doctor’s appointment is as easy as booking a dinner date.

The Booking Process: Tailored for Simplicity and Flexibility

HealthLynked’s online booking system is designed with the user experience at the forefront. The process is straightforward: patients select their preferred doctor, date, and whether they prefer a morning or afternoon appointment. This flexibility not only enhances convenience but also allows healthcare providers to manage their schedules efficiently, accommodating more patients while delivering personalized care.

Here’s How It Works:

1. Selection of Doctor and Timing: Patients can browse and select from a Directory of doctors based on specialty, availability, and ratings. Choosing a general time of day (morning or afternoon) provides the system and the healthcare provider flexibility in scheduling, which is particularly beneficial for managing daily patient volumes.
2. Reason for Visit: Patients specify the reason for their appointment, enabling the doctor to prepare in advance and tailor the consultation to the patient’s needs.
3. Personal Information: To book the appointment, patients need to provide basic information including their first and last name, date of birth, address, phone number, and email address.
4. Account Creation and Recognition: If a patient has not previously created an account, one is automatically set up upon their first booking. This account simplifies future interactions with the system by remembering user details, reducing the need to re-enter information. Returning patients can simply enter their email or phone number, and the system prompts them for their password.

First-Time and Returning Users: An Inclusive System

HealthLynked extends the convenience of this system to both new and returning patients. First-time users have the privilege of booking with any doctor across the country, broadening their options and access to healthcare. For returning patients, especially those who are free members, there is an encouragement to upgrade to a paid membership should they choose to book with an out-of-network doctor. This membership, priced at $12 per month or $10 per month when paid annually, ensures patients can consistently receive care from their preferred healthcare providers.

Why HealthLynked’s System Stands Out

This model resembles OpenTable’s approach to restaurant bookings, where ease and accessibility are paramount. HealthLynked leverages similar principles to enhance healthcare accessibility and patient satisfaction. The system not only prioritizes user convenience but also integrates advanced features that remember user preferences and streamline the booking process.

Conclusion: A Step Towards More Connected and Accessible Healthcare

By integrating a user-friendly online booking system, HealthLynked is setting a new standard in healthcare delivery. This innovation not only makes medical consultations as easy as booking a table at your favorite restaurant but also significantly improves the efficiency of healthcare services. As HealthLynked continues to refine and expand its offerings, the potential to further enhance patient engagement and satisfaction seems boundless. With such technologies, the future of healthcare is not only interconnected but also intuitively aligned with the needs and expectations of modern patients.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

Third-Party Content

The STBN website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the STBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of STBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and STBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by STBN providing you with this internet portal that makes accessible to you the ability to view third party content through the STBN site, STBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. STBN expressly disclaims liability relating to such third-party content. STBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, STBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.stockstobuynow.com/disclaimer/.

The disclaimers on the STBN website are applicable to all content provided by STBN, wherever published or re-published are at: https://www.stockstobuynow.com/disclaimer/

• SuperCom Ltd. is focused on developing its portfolio of products in support of advanced electronic monitoring (“EM”) solutions, and reported last month record-level revenues and EBITDA during the past year
• SuperCom’s recent positive financials report represents the results of the company’s efforts to introduce non-incarceration EM alternatives around the world, with inroads in Europe and the U.S. resulting in significant contracts
• Electronic technology for tracking criminal offenders and other court-administered programs provides a more economical approach to security than incarceration in cases where such options applicable

Electronic-monitoring (“EM”) security solutions developer SuperCom (NASDAQ: SPCB) has seen its revenues and gross margin grow dramatically as it serves a worldwide market for court-administered security needs and other identity technology concerns.

The technology solutions company reported its Q4 and fiscal year-end financial results April 22, noting a 51 percent jump in annual revenue (its third consecutive year of growth), a 60 percent increase in gross profits for the year and a remarkable 2,350 percent burst in its EBITDA (https://ibn.fm/ZiTb4).

The figures include a quarterly increase in the company’s gross margin to 41.4 percent. SuperCom presented the record-level results to investors in a conference call and Q&A on April 22.

“These financial metrics not only underline our strong execution, but also the increasing efficiency and scalability of our operations. During the past year, we won several award contracts in the U.S. and Europe, and we’re excited about the opportunity we see ahead,” CEO and President Ordan Trabelsi said as he introduced the conference call (https://ibn.fm/o9QOH). “Since 2018, SuperCom has secured over 50 new multi-year government projects. Our strong growing reputation as a premium provider of electronic monitoring solutions and services enhanced our market position with each new customer win.”

SuperCom is focused on developing IoT tracking opportunities using its suite of technological products, including PureProtect for domestic violence monitoring, the comprehensive PureOne GPS tracking solution and the PureSecurity platform that is being upgraded with advanced AI integration.

Along with that focus, the company also launched a new project in Iceland that involved upgrades to a system supporting the secured issuance of national ID cards and passports that had previously been deployed.

“This growth is a testament to our competitive edge and ability to secure significant contracts, such as the $33 million national domestic violence project and other multiple high-value projects in Europe and California, reflecting our commitment to excellence and our ability to meet the diverse needs of our international clientele,” Ordan said.

The PureProtect product is particularly important as a solution with life-saving potential. It provides improved protection to families suffering from domestic violence. It was a new rollout during the past year along with PureOne, which delivers a competitive all-in-one GPS tracking ankle bracelet monitoring solution tailored to the North American market.

Ordan said that high recidivism rates and the increasing costs associated with incarceration are making SuperCom’s electronic monitoring solutions an attractive alternative for governments that want to cut their costs while ensuring public safety.

During the past years, SuperCom sealed significant new contracts in a competitive bidding process, allowing the company to expand into 10 new countries in the European market, he reported.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Fast anneal is expected to impact various quantum computing applications, from advanced scientific research in quantum simulation to AI and solving real-world problems across wide spectrum of industries
• It expands upon D-Wave’s groundbreaking optimization achievements, utilizing the comprehensive coherent annealing quantum computing provided by D-Wave’s Advantage(TM) systems and the cutting-edge Advantage2(TM) prototype
• The introduction of the fast-anneal feature is poised to attract both commercial and academic researchers aiming to develop top-tier applications, broaden benchmarking investigations, and correlate heightened coherence with enhanced performance

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the launch of the fast-anneal feature, which is available on all D-Wave’s quantum processing units (“QPUs”) in the D-Wave Leap real-time quantum cloud service. Fast anneal is expected to impact a number of quantum computing applications, most notably advanced scientific research.

D-Wave’s fast-anneal feature has been a key part of the company’s research milestones, including published work in Nature Physics (2022) and Nature (2023), demonstrating the advantages of annealing quantum computing over classical algorithms for solving complex optimization problems. Now that this functionality is readily available, customers can conduct quantum computations at remarkable speeds, effectively mitigating the influence of external interferences like temperature changes and background noise, which typically impede quantum calculations.

By providing enhanced control for significantly quicker annealing durations compared to previous options, this feature sets the stage for customers to replicate and expand upon D-Wave’s groundbreaking optimization achievements utilizing the comprehensive coherent annealing quantum computing provided by D-Wave’s Advantage systems and the cutting-edge Advantage2 prototype, the most performant system the company has developed thus far.

“Providing direct access to Fast Anneal, which has been at the heart of D-Wave’s recent advancements, represents a significant step forward in our mission to provide customers with the resources they need to drive innovation and achieve extraordinary results,” said Dr. Alan Baratz, CEO of D-Wave (https://ibn.fm/WgOEf). “We believe it will further empower them to build industry-shaping applications with the most powerful quantum computing environment available today.”

Customer interest in D-Wave’s cutting-edge annealing quantum computing technology is evident through the utilization of its two Advantage2 experimental prototypes, which collectively have addressed almost eight million customer inquiries since their introduction in 2022 and 2024. The new fast-anneal feature is poised to attract both commercial and academic researchers aiming to develop top-tier applications, broaden benchmarking investigations, and correlate heightened coherence with enhanced performance.

Ed Heinbockel, president and CEO of SavantX, a D-Wave customer, welcomed the new functionality, saying that by providing direct access to quantum computing’s central nervous system, D-Wave is single-handedly opening new horizons for research on quantum computing and AI. “We believe the new capability will help us realize significant benefits of coherence on application development that we’d otherwise be unable to achieve,” he added.

The announcement was also praised by Christopher Savoie, co-founder and CEO of Zapata AI, who underlined that the ability to use the fast-anneal feature to directly interact with D-Wave’s Advantage2 prototype is exciting for Zapata AI’s work building quantum-enhanced generative AI models trained on molecular data to accelerate drug discovery and design new materials. “The fast-anneal feature can produce coherent distributions that have the potential to allow more efficient encoding of complex data patterns in a way that is classically impractical,” Savoie added. “In addition to molecular discovery applications, this feature could also be valuable in other industrial applications involving complex data patterns, particularly in combinatorial optimization problems found across industries.”

D-Wave’s customers include over two dozen Forbes Global 2000 companies and blue-chip industry leaders like Mastercard, Deloitte, Unisys, NEC Corporation, DENSO, and more. Their client success stories can be found on the company’s website (https://ibn.fm/aDOwo).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of its Quarterly Reports on Form 10-Q and in the company’s other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

• PaxMedica has completed its three registration/validation batches of PAX-101, an IV formulation of suramin
• The completed batches are a significant step toward submitting a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2024
• PaxMedica aims to establish a sustainable global supply chain for PAX-101 and to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”), demonstrating a steadfast commitment to addressing complex neurological conditions
• The ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently announced that it has completed its three registration/validation batches of PAX-101, an IV formulation of suramin. This accomplishment marks a significant step toward submitting a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the fourth quarter of 2024 (https://ibn.fm/52o4M).

This step paves the way for potential commercial availability in the U.S. of Suramin, the sole form for treating Stage 1 Human African Trypanosomiasis (“HAT”) caused by Trypanosoma brucei rhodesiense. This disease, fatal and neglected, represents a critical healthcare challenge. Pending FDA approval, this milestone is crucial for PaxMedica as it seeks FDA approval for PAX-101, pending a thorough review process., which is recognized as the standard treatment for HAT outside the United States, according to the CDC.

A favorable review and NDA approval may also position the company to receive a Tropical Disease Priority Review Voucher (“PRV”). PaxMedica aims to establish a sustainable global supply chain for PAX-101, primarily as a step financially enabling the company to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”).

ASD comes with different challenges, and PaxMedica’s robust pipeline of products may help reduce, or modulate some of the more troublesome aspects of ASD. This advancement would allow people with autism to integrate their behavior with others more successfully and improve their lives.

According to Fortune Business Insights, the ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030, expanding at a CAGR of 8.5% during the forecast period. The growing prevalence of ASD and increasing access to treatment options are encouraging more ASD patients and their families to seek treatment regimens (https://ibn.fm/aavzi).

Howard Weisman, chairperson and CEO of PaxMedica, commented on the recent developments, stating, “This completion of our registration/validation batches is a crucial step as we prepare for an NDA submission for PAX-101. It marks a significant milestone in our ongoing efforts.” He further elaborated, “Our long-term vision includes extending our clinical investigations of PAX-101 as a potential treatment for individuals with Autism Spectrum Disorder. This manufacturing achievement has significantly aided in overcoming one of the major barriers to initiating further tests on PAX-101 for addressing the core symptoms of ASD, which remain under investigation.”

“The progress we’ve made brings us closer to our objective of becoming a reliable global supplier of suramin, particularly for treating Stage 1 Human African Trypanosomiasis (‘HAT’), a condition for which suramin is recognized as one of the World’s Essential Medicines,” Weisman added. “It is our aim to eventually undertake clinical trials to explore the use of PAX-101 for the core symptoms of ASD. It is important to note that there are currently no approved medications that address these symptoms directly, making our research both challenging and essential.”

PaxMedica is on a promising path to change the future of ASD, bringing hope to millions. The company hopes to add this important new treatment option to improve the prospect of independence. It has the potential to help adolescents and young adults lead brighter, more independent lives.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05)
• Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05)
• Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified
• This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects

Clene (NASDAQ: CLNN), along with its subsidies, “Clene”, and its wholly owned subsidiary Clene Nanomedicine, Inc., a pioneering clinical-stage biopharmaceutical firm dedicated to enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative disorders such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), unveiled the comprehensive findings of the Phase 2 VISIONARY-MS long term extension (“LTE”) study at the esteemed 2024 American Academy of Neurology (“AAN”) Annual Meeting in Denver (https://ibn.fm/Ro9gg).

During the Emerging Science Session, Dr. Michael Barnett, MBBS, FRACP, FRCP, PhD, representing the University of Sydney, presented compelling data showcasing the sustained clinical, functional, and structural enhancements correlated with the daily oral administration of CNM-Au8(R) 30 mg for a remarkable period of up to three years.

These groundbreaking long-term outcomes from the Phase 2 VISIONARY-MS clinical trial underscored the compelling evidence endorsing the reparative and remyelinating effects of CNM-Au8 treatment. The extended findings build upon the trial’s earlier outcomes from the double-blind phase, which exhibited noteworthy improvements in low contrast letter acuity and the modified MS Functional Rating Scale, serving as the primary and secondary endpoints of the study, with continued enhancements noted during the LTE.

The significant and consistent results observed across a spectrum of paraclinical exploratory endpoints further reinforce the sustained clinical advantages experienced by study participants across various clinical outcome measures, aligning with the consistent enhancements in neuronal function and remyelination.

Key highlights from the “Phase 2 CNM-Au8 VISIONARY-MS Trial: Long-Term Extension Results” presentation include:

1. Enhanced Cognition and Vision

• Individuals originally assigned to CNM-Au8 treatment demonstrated continued substantial enhancement in vision, evidenced by significant improvements in low contrast letter acuity. More than half of the participants exhibited improvements of 10 or more letters on a low-contrast Sloan eye chart, with some achieving increases of up to 38 letters (vs. original baseline, p < 0.001 via mixed model repeat measures analysis, or MMRM).
• Participants initially assigned to placebo, subsequently transitioning to CNM-Au8 following the 48-week double-blind period, also experienced noteworthy improvement in vision, as demonstrated by low contrast letter acuity after receiving treatment with CNM-Au8 30 mg (vs. original baseline, p < 0.05 via MMRM).
• Subjects treated with CNM-Au8 demonstrated significant enhancements of up to 29 points (max score =110) in cognition and working memory as measured by the Symbol Digit Modality Test (“SDMT”) (vs. original baseline, p < 0.001 via MMRM).

2. Physiologic Evidence of Repair and Remyelination

• Participants receiving CNM-Au8 treatment showcased substantial improvements in both amplitude (vs. original baseline, p < 0.01 via MMRM) and latency (vs. original baseline, p = 0.06 via MMRM) as measured by multi-focal visual evoked potentials, serving as physiological indicators of signal strength and speed along the visual pathway, indicative of neuronal health and remyelination, respectively.

3. Structural Evidence of Repair and Remyelination:

• MRI evaluations of axial diffusivity exhibited significant enhancements in T2 brain lesions among study participants treated with CNM-Au8 (vs. original baseline, p < 0.05 via MMRM).
• MRI assessments of T2 lesion myelin water fraction (“MWF”) and magnetization transfer ratio (“MTR”), both indicative of remyelination, demonstrated improvements following long-term CNM-Au8 treatment (MWF: vs. original baseline, p < 0.05 via MMRM; MTR: vs. original baseline, p = 0.06 via MMRM).

CNM-Au8 exhibited excellent tolerability, with no significant safety concerns identified.

“Observing such a profound clinical benefit with corresponding improvements in physiologic measures utilizing a mechanism that does not target immune system modulation has never been demonstrated in prior multiple sclerosis trials,” said Dr. Benjamin Greenberg, Head of Medicine for Clene. “This is a very exciting data set that gives hope to the millions of people who are suffering from this disabling disease.”

The presentation is available on the company’s website at https://ibn.fm/06tSN.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Fr8Tech, a tech company on a mission to revolutionize cross-border shipping, just posted 30% year-over-year (“YOY”) revenue growth and a 278% YOY growth in Fr8Fleet volume for Q1 2024
• This growth was attributed to the addition of the Fr8Fleet offering in 2022, which sought to address specific customer needs
• The company looks to build on this success by fostering even stronger relationships with existing customers and adding new customers to its network
• Its management believes that this approach will be integral in realizing its $25-$30 million annual revenue projection for the 2024 financial year

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers and shippers flexibility, visibility, and simplicity, just released preliminary financial results for the first quarter of the 2024 financial year (“Q1 2024”). Of note was the 30% revenue growth over the same period in the previous year, totaling $4.3 million. The company also reported a 25% growth in volume for Fr8Fleet from the fourth quarter of the 2023 fiscal year and a 278% year-over-year growth with approximately 3,400 completed shipments (https://ibn.fm/ir97f).

According to the company’s management, this growth and impressive performance was primarily attributed to adding the Fr8Fleet offering, which sought to address specific customer pain points by securing dedicated carrier capacity and providing responsive, high-quality customer service.

“The company’s addition of its Fr8Fleeet offering in 2022 was the right strategic response to the market dynamics of the Mexican domestic Over the Road (“OTR”) freight industry,” noted Don Quinby, Fr8Tech’s Chief Financial Officer (“CFO”).

“It has proven to be a highly valued service for large enterprise customers and is a key differentiator for Fr8Tech,” he added.

Fr8Tech looks to build even stronger relationships with its new and existing customers. Additionally, it is committed to bolstering its carrier capacity while improving its platform’s capabilities and efficiency, which has been a game-changer in the industry. According to its CEO and Director, Javier Selgas, focusing on these aspects will allow the company to realize its 2024 annual revenue projections of between $25 and $30 million.

“Underlying economic activity in both Mexico and the US, coupled with ongoing near-shoring activity of US and foreign multinational companies, suggests continued growing demand for domestic and cross-border freight services,” noted Mr. Selgas.

“We are well positioned to take advantage of this market opportunity, and the Fr8Tech team continues to innovate to make market share gains over the coming year,” he concluded.

If recent events in the region are anything to go by, Fr8Tech anticipates a significant uptick in the demand for its products and services. Earlier in the year, railroad disruptions, owing to a surge in smuggling of migrants through Mexico, saw nearly 10,000 rail cars stranded on both sides of the border (https://ibn.fm/wch92). Such events have forced companies to explore more reliable options, and Fr8Tech offers just that and more. With its market positioning, distinctive freight matching capabilities and easy-to-use features of its platform, the company is confident that it will bring plenty of industry participants together through Fr8App to meet its revenue projections for the year.

For more information, visit the company’s website at www.Fr8Technologies.com and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• SUIC recently announced that I.Hart Group Taiwan and MONGA(C) Fried Chicken had signed franchise authorizations in Japan and China
• The franchise authorizations are expected to grow the number of stores operated by I.Hart Group to 200 outlets in 2024 and more than 500 stores over the next five years
• The authorizations covering Shandong Province in China will see the Shandong Authorized company opening ten stores during the first year and 300 stores within the subsequent five years. Japan is another authorization which will target the greater Tokyo metropolitan area
• The new authorizations are part of SUIC’s commitment to grow its footprint in the global food market and serve more customers around the world

SUIC Worldwide Holdings (OTC: SUIC) is a company helping build tech-enabled businesses of the future by providing research and development and venture financing as well as investing in enterprises that develop products and services adopting core capabilities of the Internet of Things, cloud computing, mobile payment, big data, blockchain, and artificial intelligence. SUIC is the biggest investor, shareholder, and major operating partner of Beneway USA, a company whose wholly owned subsidiary, I.Hart Group Taiwan, is making strides in the global food industry.

I.Hart Group currently operates 150 global franchised locations in different countries under various brands and products, including MONGA(C) Taiwan-style Fried Chicken, flower tea drinks, dumplings, cloud kitchen management, AI smart machines, and more. As of February 2024, I.Hart Group had a total of 90 MONGA(C) Fried Chicken stores and outlets in 10 countries (https://ibn.fm/j1bJ4), but this number is set to grow following recent developments.

SUIC recently announced that I.Hart Group and MONGA(C) Fried Chicken had signed franchise authorizations in Japan and China, which are expected to expand significantly the presence of both companies by growing the number of I.Hart Group’s MONGA(C) Fried Chicken outlets initially to 95, across 11 countries (https://ibn.fm/6Fqe5).

The authorizations in China cover 16 cities across Shandong, China’s second-largest province, with a population of more than 100 million. According to SUIC, the Shandong Authorized company has committed to opening ten stores during the first year and 300 stores within the subsequent five years. To make this ambitious goal a reality, I.Hart Group and the Shandong Authorized company, in conjunction with at least 50 or more franchise owners every year, will work together to operate MONGA(C) Fried Chicken stores in various locations within the province.

Additionally, the signed franchise authorizations in Japan cover the expansive city of Tokyo and its surrounding satellite cities, home to more than 38 million people. The authorizations aim to tap into the region’s status as the world’s largest metropolitan area, representing a potentially large market for the stores. Moreover, the Greater Tokyo metropolitan area’s GDP is second only to the New York metropolitan area, signaling the health of the city’s economy and, by extension, the ability of its populace to buy consumer goods like the food offered at the MONGA(C) Fried Chicken outlets.

“We dedicate our team and resources to the success and expansion of our franchise development efforts and global transformation journey. We will continue to increase this momentum in 2024 and find opportunities in serving more customers around the world, growing our footprint in the global food market by tenfold,” commented Hank Wang, SUIC CEO.

According to the company, the new franchise authorizations will lead to the opening of new franchises, increasing the number of stores operated by I.Hart Group to 200 outlets in 2024 and more than 500 stores over the next five years.

For more information, visit the company’s website at www.SinoUnitedCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SUIC are available in the company’s newsroom at https://ibn.fm/SUIC

• Industrial and commercial buildings are responsible for a significant amount of the carbon emissions affecting the planet’s climate, according to pollution experts
• Correlate Energy Corp. is a distributed energy solutions company, focusing on the North American market, that is dedicated to helping client companies improve their energy use profiles, reducing emissions while maintaining their budgets
• Correlate is strategically positioned to leverage government financial incentives on its clients’ behalf, as well as offering an array of modern, targeted tools to achieve data-driven solutions
• The company currently has about $150 million of in-progress projects in various stages of development

The drive to reduce carbon emissions and improve energy use efficiency for corporate and government office buildings is increasingly driving strategy sessions on climate change, amid efforts to meet the goals of the past decade’s UN-brokered Paris Agreement to battle carbon-based pollution worldwide.

In the European Union, where the ruling council announced earlier this month that it has formally adopted the more stringent climate plan regulations of its Energy Performance of Buildings Directive (https://ibn.fm/J9o8q), buildings account for about 40 percent of the league of states’ energy consumption, with more than half of its gas consumption and 35 percent of the energy-related greenhouse gas emissions (https://ibn.fm/PTg0O).

Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is welcoming the international attention on industrial and commercial building energy use. The company has demonstrated the ability to create stockholder value while facilitating this building utility trend, offering to finance, develop, and profitably sell localized clean energy solutions and microgrids to industrial, commercial, and residential customers.

Correlate’s focus is on the North American market, working with government incentives and other financial opportunities to help clients find an affordable way to step up their energy use infrastructure.

“We have this constant conveyor belt of a maturity of opportunities (that) really allows us to smartly invest in different parts of the business from origination of sales to construction and oversight,” Correlate Energy President and CEO Todd Michaels told Proactive Investors (https://ibn.fm/8MA23). “Solar’s the most applicable technology. Right now it’s basically beating the grid for costs … so that’s the lead horse. In behind that comes things like batteries, where if somebody wants to have resiliency — let’s say the grid goes down in Texas or California or the Northeast, which is very prevalent nowadays — things like storage can allow them to have 24 / 7 uninterrupted operations.”

By leveraging opportunities with clients that have dozens of locations across the country, Correlate is providing retrofit upgrades at a number of sites, while positioning itself to scale up by retaining ownership of some of its energy systems and acquiring promising renewable energy companies.

The company currently has about $150 million worth of projects being completed, according to its officers.

Correlate announced a partnership with Carbonsight (by Autocase) in February that is strengthening its ability to take a data-driven approach to its decarbonization planning process. The Carbonsight software makes it easier for building portfolio managers to quantify costs, savings and timelines for putting their targeted energy projects into motion (https://ibn.fm/tqvTV).

The company is also utilizing Xendee’s distributed energy resource platform as a tool to effectively complete the site analysis process and design proposals for projects, Chief Product Officer Leif Elgethun said in a recent webinar.

With cutting-edge tools and financing options that were unknown just a few years ago, the company is becoming a significant partner in the worldwide effort to reduce carbon emissions.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• PCPs play pivotal role in successful healthcare approach
• Evidence shows that primary care helps prevent illness and death
• Astiva Health has established a healthcare ecosystem where best PCPs are rewarded for expertise, commitment

The importance of primary care in a successful healthcare approach has been clearly shown through decades of research. Astiva Health is dedicated to enhancing the quality of medical care through a strong doctor-patient relationship with the success of its model hinging on knowledgeable, competent, and hard-working primary care physicians (“PCPs”) who play a pivotal role in the healthcare system.

“Evidence of the health-promoting influence of primary care has been accumulating ever since researchers have been able to distinguish primary care from other aspects of the health services delivery system,” states a National Library of Medicine research report (https://ibn.fm/aRCQx). “This evidence shows that primary care helps prevent illness and death, regardless of whether the care is characterized by supply of primary care physicians, a relationship with a source of primary care, or the receipt of important features of primary care. The evidence also shows that primary care (in contrast to specialty care) is associated with a more equitable distribution of health in populations, a finding that holds in both cross-national and within-national studies.”

With this in mind, Astiva Health is dedicated to establishing a healthcare ecosystem where the best primary care doctors are not only rewarded for their expertise but also for their commitment to providing the best possible care. Astiva Health advocates for a physician-led approach that motivates primary care physicians to provide exceptional care. By offering incentives for doctors who show remarkable dedication and achieve excellent patient outcomes, Astiva emphasizes its commitment to a model that financially rewards PCPs for their outstanding performance.

In addition, Astiva Health collaborates with more than 60 physician groups with a focus on empowering PCPs to excel by allowing them more time for patient interactions through the strategic use of technology. This not only enhances the quality of consultations but also integrates care by providing real-time access to health data. This system ensures seamless communication with government health systems, further improving the efficacy of healthcare delivery.

The company is also dedicated to simplifying processes for doctors, achieving an impressive approval rate for requests and significantly reducing review times. Astiva Health’s streamlined approach includes an optimized annual wellness visit form, now condensed to only three pages. This concise form is designed to be filled out efficiently by physicians and their staff, saving valuable time and allowing them to focus more on patient care rather than paperwork. Together with the conversion of the form from paper to electronic format and a new hosting system, patients’ health data now can be transferred from providers’ office to Astiva accurately in real time. This initiative is part of the company’s commitment to enhancing operational efficiency and supporting healthcare providers in delivering top-notch care efficiently.

Finally, Astiva Health actively works with its patients to facilitate more frequent doctor visits, supporting a model that rewards physicians for top-tier primary care services. By aligning incentives and employing a unified system for doctor-patient interactions, Astiva Health fosters a proactive environment where primary care thrives, ultimately benefiting the overall health and well-being of their patients.

PCPs are recognized as the gatekeepers to specialists, often determining the frequency of patient visits and overseeing comprehensive care management. Astiva Health’s holistic approach underscores the company’s understanding that effective primary care is foundational, requiring a unique blend of expertise and dedication to maintain stability and control within the healthcare system.

Astiva Health advocates for a healthcare ecosystem where the best doctors are not only rewarded for their expertise but also for their commitment to providing the best possible care. This model naturally encourages preventative primary care, a cornerstone of Astiva’s philosophy, highlighting how preventive measures are not only beneficial for health but also significantly more cost-effective than reactive care following emergency situations.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

BioLargo (OTCQB: BLGO), a pioneering cleantech and life sciences company, has made significant strides with its Aqueous Electrostatic Concentrator (“AEC”) technology, setting a new benchmark in the water treatment industry. This innovative technology has proven to effectively remove per- and polyfluoroalkyl substances (“PFAS”) from water, surpassing the stringent new U.S. Environmental Protection Agency (“EPA”) drinking water standards for PFAS chemicals set to take effect on April 10, 2024. The AEC technology’s ability to generate significantly less PFAS-laden solid waste compared to traditional methods like carbon filtration or ion exchange positions it as a potentially more sustainable and cost-effective solution for water providers.

The importance of BioLargo’s breakthrough cannot be overstated, especially in light of the EPA’s newly finalized regulations that aim to limit PFAS in public drinking water to nearly undetectable levels, as low as 4 parts per trillion. PFAS chemicals, which are used in various consumer goods and industrial applications, have been linked to serious health issues, including cancer and developmental problems. Traditional water treatment technologies often fall short in efficiently removing certain PFAS compounds and tend to produce large volumes of hazardous waste. In contrast, BioLargo’s AEC technology not only meets but exceeds these new EPA standards for all PFAS contaminants, offering a more sustainable and cost-effective solution for water providers.

The company’s commitment to addressing the challenges posed by PFAS contamination extends beyond the development of its AEC technology. BioLargo also provides advisory services, analytical testing, and education on PFAS science and regulations to assist water providers in navigating the complexities of compliance with the new rules. This comprehensive approach underscores BioLargo’s dedication to supporting its customers through innovative technology and expert guidance.

The financial implications of BioLargo’s technological advancements are also noteworthy. The company’s stock price saw an increase of approximately 4.93% to $0.35, reflecting investor confidence in its potential for growth and profitability. With a market capitalization of around $103.9 million and a trading volume of 122,885 shares, BioLargo is demonstrating its capacity to capture the attention of the investment community. The fluctuation in stock price, ranging from a low of $0.15 to a high of $0.45 over the past year, indicates a growing interest in the company’s solutions for environmental and cleantech challenges.

In conclusion, BioLargo, Inc. is at the forefront of addressing some of the most pressing environmental issues of our time, particularly PFAS contamination in water. Through its AEC technology, the company is not only meeting but exceeding new EPA standards, offering a more sustainable and cost-effective solution for water providers. With its comprehensive approach to tackling PFAS contamination and its promising financial performance, BioLargo is well-positioned to make a significant impact in the cleantech and life sciences sectors.

For more information, visit the company’s website at www.BioLargo.com.